New chemotherapy timing tests for locally advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 3 trial compares two chemotherapy combinations given with surgery for locally advanced rectal cancer. It aims to find out which approach works better and is safer for shrinking and controlling the cancer before or around the time of treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed rectal cancer seen on biopsy (rectal adenocarcinoma).
- Imaging (CT/MRI/other scans) shows the cancer can be removed with surgery and there are no distant metastases.
- You are age 18 or older, and your general fitness is good (ECOG 0–1).
- You have not had any prior cancer treatment, especially no radiation to the pelvis.
- Your tumor is within a certain distance low in the rectum, and your scan stage fits specific local spread categories.
- Your genetic test shows UGT1A1 is normal (wild-type) or only mildly changed (single heterozygous).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a “smart” total treatment plan using chemotherapy (chemo) and radiation before surgery for people with locally advanced rectal cancer. The goal is to see if this approach is safe and can work well while helping plan treatment based on your situation.
This trial tests a combination of chemotherapy, radiation, and an immunotherapy drug (PD-1 inhibitor) before surgery for locally advanced rectal cancer located below the peritoneal reflex. The goal is to see if this approach improves outcomes.
This study tests two different radiation regimens (long-course vs. short-course) combined with chemotherapy (CAPOX), an immunotherapy drug (PD-1 antibody), and a COX-2 inhibitor for people with MSS locally advanced rectal cancer. The goal is to see which approach works better in shrinking the tumor before surgery.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This study tests a sequence of chemotherapy and radiation before and after surgery for rectal cancer. It compares giving more chemo between the end of radiation and surgery (consolidation) versus giving some chemo before radiation starts (induction). The goal is to see which order works better.
This trial tests a new combination for rectal cancer that hasn't spread far: a short course of radiation followed by two drugs (AK112 and CAPOX). The goal is to shrink the tumor before surgery and possibly avoid more aggressive treatments.
Hear when a new Locally Advanced Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.